Literature DB >> 1532403

"Plasminogen steal" and clot lysis.

S R Torr1, D A Nachowiak, S Fujii, B E Sobel.   

Abstract

Although initially developed to reduce the risk of bleeding, second-generation (clot-selective) thrombolytic agents have been found to induce more prompt and frequent recanalization than do nonselective, first-generation agents. To determine whether they do so in part by preserving clot-associated plasminogen, human whole blood clots formed in Chandler tubes were studied. Addition of suprapharmacologic concentrations of recombinant tissue-type plasminogen activator (rt-PA) to the media bathing mature clots led to a paradoxic impairment of clot lysis and a concomitant concentration-dependent depletion of clot-associated plasminogen (Western blot analysis). In contrast, supplementation of the plasma with plasminogen (0.27 mg/ml) led to significant conservation of both plasma and clot-associated plasminogen (p less than or equal to 0.05, n = 4), and prevented the diminution of clot lysis (p less than or equal to 0.05; n = 4). Fibrinogen degradation products did not account for the attenuation of lysis with the highest concentrations of rt-PA. In concentrations equivalent to those that were induced by the highest concentrations of rt-PA evaluated, fibrinogen degradation products potentiated rather than inhibited lysis (p less than or equal to 0.05, n = 4), probably by stimulating rt-PA activity directly. When preformed clots were incubated with plasminogen-depleted plasma plus 1,000 ng/ml rt-PA, the plasminogen content in residual clot declined (9.36 +/- 0.46 versus 12.39 +/- 0.69 ng/mg clot found in nondepleted plasma; p less than or equal to 0.05; n = 6). Furthermore, clot lysis was attenuated completely.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1532403     DOI: 10.1016/0735-1097(92)90300-c

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  12 in total

1.  A catalytic switch and the conversion of streptokinase to a fibrin-targeted plasminogen activator.

Authors:  G L Reed; A K Houng; L Liu; B Parhami-Seren; L H Matsueda; S Wang; L Hedstrom
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-03       Impact factor: 11.205

2.  Achieving Optimal Reperfusion without Adjunctive Antithrombotic Therapy: Novel Thrombolytic Dosing Strategies.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

3.  Combination treatment with rt-PA is more effective than rt-PA alone in an in vitro human clot model.

Authors:  Jason M Meunier; Christy K Holland; Tyrone M Porter; Christopher J Lindsell; George J Shaw
Journal:  Curr Neurovasc Res       Date:  2011-11       Impact factor: 1.990

4.  Purification and characterization of a fibrinolytic subtilisin-like protease of Bacillus subtilis TP-6 from an Indonesian fermented soybean, Tempeh.

Authors:  Seong-Bo Kim; Dong-Woo Lee; Chan-Ick Cheigh; Eun-Ah Choe; Sang-Jae Lee; Young-Ho Hong; Hak-Jong Choi; Yu-Ryang Pyun
Journal:  J Ind Microbiol Biotechnol       Date:  2006-02-10       Impact factor: 3.346

5.  Reprogrammed streptokinases develop fibrin-targeting and dissolve blood clots with more potency than tissue plasminogen activator.

Authors:  I Y Sazonova; R A McNamee; A K Houng; S M King; L Hedstrom; G L Reed
Journal:  J Thromb Haemost       Date:  2009-06-30       Impact factor: 5.824

Review 6.  Can the time window for administration of thrombolytics in stroke be increased?

Authors:  Geoffrey A Donnan; David W Howells; Romesh Markus; Danilo Toni; Stephen M Davis
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

7.  The use of the Chandler loop to examine the interaction potential of NXY-059 on the thrombolytic properties of rtPA on human thrombi in vitro.

Authors:  N J Mutch; N R Moore; C Mattsson; H Jonasson; A R Green; N A Booth
Journal:  Br J Pharmacol       Date:  2007-11-05       Impact factor: 8.739

8.  Effect of Reteplase and PAI-1 antibodies on postoperative adhesion formation in a laparoscopic mouse model.

Authors:  Maria Mercedes Binda; Bart W J Hellebrekers; Paul J Declerck; Philippe Robert Koninckx
Journal:  Surg Endosc       Date:  2008-09-24       Impact factor: 4.584

9.  Subacute recanalization and reocclusion in patients with acute ischemic stroke following endovascular treatment.

Authors:  Adnan I Qureshi; Haitham M Hussein; Mohamed Abdelmoula; Alexandros L Georgiadis; Nazli Janjua
Journal:  Neurocrit Care       Date:  2008-12-03       Impact factor: 3.210

10.  Tissue plasminogen activator (tPA) inhibits plasmin degradation of fibrin. A mechanism that slows tPA-mediated fibrinolysis but does not require alpha 2-antiplasmin or leakage of intrinsic plasminogen.

Authors:  J H Wu; S L Diamond
Journal:  J Clin Invest       Date:  1995-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.